These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 569783

  • 1. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders.
    Tabaddor K, Wolfson LI, Sharpless NS.
    Neurology; 1978 Dec; 28(12):1249-53. PubMed ID: 569783
    [Abstract] [Full Text] [Related]

  • 2. Reye syndrome: monoamine metabolites in ventricular fluid.
    Shaywitz BA, Venes J, Cohen DJ, Bowers MB.
    Neurology; 1979 Apr; 29(4):467-72. PubMed ID: 571546
    [Abstract] [Full Text] [Related]

  • 3. Hemiballismus: changes in cerebrospinal fluid.
    Kostic V, Djuricic B, Paschen W.
    Acta Neurol Scand; 1988 Aug; 78(2):115-7. PubMed ID: 2459894
    [Abstract] [Full Text] [Related]

  • 4. CSF HVA and 5-HIAA.
    Wood JH.
    Neurology; 1979 Jun; 29(6):910-12. PubMed ID: 572023
    [No Abstract] [Full Text] [Related]

  • 5. Diminished ventricular fluid dopamine metabolites in adult-onset dystonia.
    Tabaddor K, Wolfson LI, Sharpless NS.
    Neurology; 1978 Dec; 28(12):1254-8. PubMed ID: 569784
    [Abstract] [Full Text] [Related]

  • 6. [Central metabolism of dopamine and serotonin. II. Significance of cerebrospinal fluid HVA and 5-HIAA changes in extrapyramidal and cerebellar syndromes].
    Buscaino GA, Mandarini A, Campanella G, Carrieri P, Orefice G.
    Acta Neurol (Napoli); 1976 Dec; 31(5):565-70. PubMed ID: 138340
    [No Abstract] [Full Text] [Related]

  • 7. [HVA and 5-HIAA in the cerebrospinal fluid in extrapyramidal and cerebrellar syndromes. Preliminary data].
    Carrieri P, Mandarini A, Campanella G.
    Acta Neurol (Napoli); 1975 Dec; 30(5):449-54. PubMed ID: 132845
    [No Abstract] [Full Text] [Related]

  • 8. Monoamine metabolites in successive samples of spinal fluid. A comparison between healthy volunteers and patients with multiple sclerosis.
    Andersen O, Johansson BB, Svennerholm L.
    Acta Neurol Scand; 1981 Apr; 63(4):247-54. PubMed ID: 6163303
    [Abstract] [Full Text] [Related]

  • 9. [Homovanillic (HVA) and 5-hydroxyindoleacetic (5-HIAA) acid concentration in the cerebrospinal fluid of patients with supratentorial tumors and symptoms of intracranial hypertension (preliminary report)].
    Majchrzak H, Kmieciak-Kołada K, Herman Z, Wencel T.
    Neurol Neurochir Pol; 1980 Apr; 14(1):87-90. PubMed ID: 6154903
    [Abstract] [Full Text] [Related]

  • 10. Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
    Soininen H, MacDonald E, Rekonen M, Riekkinen PJ.
    Acta Neurol Scand; 1981 Aug; 64(2):101-7. PubMed ID: 6172950
    [Abstract] [Full Text] [Related]

  • 11. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid.
    Vaughn DM, Coleman E, Simpson ST, Satjawatcharaphong C.
    Am J Vet Res; 1988 Aug; 49(8):1302-6. PubMed ID: 2459997
    [Abstract] [Full Text] [Related]

  • 12. Diminished levels of ventricular fluid norepinephrine metabolite and somatostatin in childhood-onset dystonia.
    Wolfson LI, Sharpless NS, Thal LJ.
    Adv Neurol; 1988 Aug; 50():177-81. PubMed ID: 2456674
    [No Abstract] [Full Text] [Related]

  • 13. Homovanillic acid and 5-hydroxyindoleacetic acid in the ventricular CSF of comatose patients with obstructive hydrocephalus.
    Inagawa T, Ishikawa S, Uozumi T.
    J Neurosurg; 1980 May; 52(5):635-41. PubMed ID: 6154788
    [Abstract] [Full Text] [Related]

  • 14. Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy.
    Shaywitz BA, Cohen DJ, Bowers MB.
    Neurology; 1975 Jan; 25(1):72-9. PubMed ID: 803305
    [Abstract] [Full Text] [Related]

  • 15. Concentration of homovanillic acid and 5-hydroxyindoleacetic acid in the ventricular cerebrospinal fluid of patients with obstructive hydrocephalus.
    Kmieciak-Kolada K, Majchrzak H, Herman ZS.
    J Neurol Neurosurg Psychiatry; 1979 Jan; 42(1):78-81. PubMed ID: 216782
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G, Algeri S, Cerletti C, Dolfini E, Jori A, Rinaldi F.
    Eur J Clin Pharmacol; 1977 Apr 20; 11(4):255-61. PubMed ID: 862646
    [No Abstract] [Full Text] [Related]

  • 18. Determination of HVA and 5-HIAA in ventricular CSF of patients with brain tumors.
    Porta M, Bareggi SR, Collice M, Ferrara M, Calderini G, Morselli PL.
    J Neurosurg Sci; 1974 Apr 20; 18(3):157-63. PubMed ID: 4465414
    [Abstract] [Full Text] [Related]

  • 19. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J, van Praag HM, Schut D, Nienhuis RJ, Lakke JP.
    Eur Neurol; 1974 Apr 20; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.